Gemina Laboratories Commences Trading on the OTCQB Market in the United States

Gemina Labs Announces Addition to its IP Portfolio

Gemina Labs Announce Signing of First Strategic License Deal

Gemina Labs Strategic Update: Focusing on Respiratory Infections and Strategic Partnerships

Gemina Announces Closing of $910,000
Convertible Note Financing

Gemina Labs appoints Stifel as Financial Advisor

Gemina Labs announces major breakthrough in environmentally friendly lateral flow test design by removing the requirement for nitrocellulose

Gemina to participate in poster session at AACC scientific meeting

Gemina Labs and ReadyGo Diagnostics achieve Mycobacterium Tuberculosis diagnosis in saliva

Gemina Labs Antibody Immobilization Chemistry Platform Demonstrates Major Lateral Flow Assay Performance Improvement

Gemina Labs announces closing of private placement

Gemina Labs to Host Investor Webinar on March 30, 2023

Gemina Appoints Diagnostic Strategist Martha Najib to the Board

Gemina appoints healthcare industry leader, Dr Bola Grace to the Board of Directors

Top ranked UK analyst and scientist, Dr Stefan Hamill appointed VP for Strategy

Gemina Labs strategic update: Focus on respiratory infections and new strategic partnerships on the horizon

Gemina Labs completes influenza A/B diagnostic test prototype

Gemina appoints Dr Michael Shannon as Chair of Clinical Advisory Board

Gemina announces collaboration on next-generation biosensors

Gemina's recent investment into RAPIvD sees immediate progress

Announcement of strategic stake in UK-based rapid test optimizer, RAPIvD

Gemina enters into license and manufacturing agreements

Gemina presents at the H.C. Wainwright Global Investment Conference

Diagnostic executive, Brian Firth, appointed as CEO

Closing of concurrent private placement announced

Closing of prospectus supplement offering and update to concurrent non-brokered private placement

Filing of prospectus supplement

Gemina announces proposed financing up to $5 million

Point-of-care diagnostic executive, Brian Firth, appointed as advisor

CE Mark for first product – the best-in-class LEGIO-X COVID test

Successful human clinical performance evaluation on LEGIO X COVID-19 TEST

Phase 2 human patient testing for initial diagnostic test nears completion

Technical development update for initial diagnostic test and filing of new IP

Gemina establishes UK subsidiary and appoints David Browning as Head of Productization

Strategic Update: From platform to product. Gemina provides a technology roadmap

Gemina Labs announces completion of significant development step for its SARS-COV-2 rapid test

Gemina Labs appoints Mike Catt as Senior Scientific Adviser

Gemina Labs announces closing of oversubscribed private placement

Gemina Labs announces private placement

Positive initial manufacturing results for Covid diagnostic test

Update on R&D activities, company milestones and corporate development initiatives

Gemina expands development competencies with three new appointments

Gemina Labs is pleased to announce that the common shares of the Company have begun trading on the Canadian Securities Exchange

​

​

​

​

​

​

​